Commodity Channel Index
|Bid||0.00 x 900|
|Ask||23.99 x 1400|
|Day's Range||23.14 - 24.46|
|52 Week Range||13.67 - 27.80|
|Beta (5Y Monthly)||1.61|
|PE Ratio (TTM)||11.85|
|Earnings Date||Jul 29, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.85|
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in June:
Today we will run through one way of estimating the intrinsic value of Exelixis, Inc. (NASDAQ:EXEL) by taking the...
Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors. The data from three expansion cohorts of the COSMIC-021 trial will be presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20). Results from the non-small cell lung cancer (NSCLC) and the metastatic castration-resistant prostate cancer (CRPC) cohorts will be presented as posters, and results from the urothelial carcinoma (UC) cohort will be presented as a poster discussion; all three presentations will be available on demand for ASCO20 registrants beginning Friday, May 29 at 8:00 a.m. ET.
Exelixis (NASDAQ: EXEL) and bluebird bio (NASDAQ: BLUE) are two biotech companies that have been moving in opposite directions on the stock market this year. While Exelixis has provided healthy gains -- its stock is up by 52.1% year to date -- Bluebird's shares have slid by 35.2% since the beginning of the year. With this backdrop in mind, it might be tempting to pick Exelixis as the better stock to buy.
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in May:
Exelixis (EXEL) delivered earnings and revenue surprises of 15.38% and 6.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Exelixis, Inc. (NASDAQ:EXEL) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 5, 2020 at 5:00 PM Eastern Time. ...
Exelixis : "I've liked this one all the way," said Jim Cramer to a caller during the 'Lightning Round' of Mad Money Thursday night. Exelixis is a genomics-based drug discovery company and the producer of Cometriq, a treatment approved for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. In this daily bar chart of EXEL, below, we can see that prices made a huge upside price gap or void last month.
Exelixis (NASDAQ:EXEL) shares have had a really impressive month, gaining 60%, after some slippage. And the full year...
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2020 financial results will be released on Tuesday, May 5, 2020 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.
Exelixis shares was roughly unchanged Tuesday, holding gains after a massive 21% jump on Monday amid positive test results for a new cancer medicine. The South San Francisco-based company saw a positive improvement to its IBD Relative Strength (RS) Rating on Tuesday, with an upgrade from 84 to 95. The rating upgrade came after Exelixis and partner Bristol-Myers Squibb on Monday announced positive results in a Phase 3 test of a kidney cancer treatment.
The company's stock soared Monday on results from a late-stage clinical trial pairing with a major cancer immunotherapy.
Exelixis stock rocketed Monday after the biotech company's Bristol Myers Squibb-partnered kidney cancer treatment succeeded in a Phase 3 test. The duo tested Cabometyx plus Opdivo.
A kidney-cancer drug candidate combining treatments from Bristol-Myers and Exelixis met its primary endpoint of progression-free survival, the companies said. Exelixis shares jumped on the report.
Shares of Exelixis Inc. shot up 8.1%, while Bristil-Myers Squibb Co.'s stock slipped 0.3% in premarket trading Monday, after the companies said a phase 3 study of a treatment for kidney cancer met its primary and secondary endpoints. "The results from the pivotal CheckMate -9ER trial clearly demonstrate the combination of cabozantinib plus nivolumab provides a clinically meaningful benefit in the key efficacy measures of progression-free survival and overall survival for previously untreated kidney cancer patients," said Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute. The stocks' moves come in the face of a broad-market selloff, with futures for the S&P 500 falling 1.5%.
BMS and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo in Combination with CABOMETYX...
Bristol Myers Squibb Co said on Monday that its blockbuster cancer immunotherapy Opdivo performed well in two separate late-stage trials, prolonging survival in previously untreated patients with kidney cancer and lung cancer. Opdivo is one of Bristol’s top-selling drugs, but sales of the drug have slowed in recent years as it has been eclipsed by Merck & Co’s rival drug Keytruda. New Jersey-based Bristol said Opdivo used in combination with Exelixis Inc's drug Cabometyx significantly improved progression-free survival - a measure of the drugs' ability to delay the disease worsening - in patients with advanced kidney cancer.
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in a fireside chat as part of the 19th Annual Needham Healthcare Conference on Wednesday, April 15, 2020 at 11:20 AM EDT / 8:20 AM PDT. Due to the ongoing COVID-19 pandemic, the conference has been converted to a virtual event.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX as a treatment for patients with curatively unresectable or metastatic renal cell carcinoma (RCC).